In this Phase 4 international study , efficacy and safety of paricalcitol-centred therapy were compared with that of cinacalcet-centred therapy for the treatment of chronic kidney disease ( CKD ) - associated secondary hyperparathyroidism ( SHPT ) in patients undergoing haemodialysis ( ClinicalTrials.gov identifier NCT00977080 ) .